advertisement
Abstract #10680 Published in IGR 6-2
The effect of surface area expansion with pericardial membrane (preclude) in Ahmed glaucoma valve implant surgery
Hwang JM; Kee CJournal of Glaucoma 2004; 13: 335-9
PURPOSE: To compare the efficacy of Ahmed glaucoma valve (AGV) implant with and without surface area expansion using pericardial membrane (Preclude) in the treatment of complicated glaucoma. PATIENTS AND METHODS: Ten eyes of AGV implant surgery using pericardial membrane (Preclude) that were designed to have surface area of 300 mm (e-AGV group) and 10 eyes of AGV implant surgery without surface area extension (AGV group) were enrolled in this prospective, randomized controlled trial study. RESULTS: Two (20%) of 10 eyes in the e-AGV group, and 8 (80%) of 10 eyes in the AGV group experienced the hypertensive phase (P = 0.007). Complete success rate was 90% in the e-AGV group and 70% in the AGV group (P = 0.291). Mean number of preoperative antiglaucoma medication was 2.4 ± 0.5 and 1.9 ± 0.3 for the e-AGV and AGV groups, respectively, and that of postoperative antiglaucoma medication was 0.1 ± 0.3 and 0.4 ± 0.7 for the e-AGV and AGV groups, respectively, at final follow-up (P = 0.229). CONCLUSION: Surface area expansion with pericardial membrane (Preclude) in AGV implant surgery resulted in a statistically significantly lower rate of hypertension without causing any postoperative complications.
Department of Ophthalmology, Seoul National University Bundang Hospital, Seoul, Korea.
Classification:
12.8.2 With tube implant or other drainage devices (Part of: 12 Surgical treatment > 12.8 Filtering surgery)
